Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $2,303 - $2,611
-48 Reduced 0.62%
7,678 $416,000
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $94,536 - $112,807
1,950 Added 33.76%
7,726 $396,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $115 - $129
-2 Reduced 0.03%
5,776 $335,000
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $36,310 - $39,990
-500 Reduced 7.96%
5,778 $445,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $37,272 - $43,451
-695 Reduced 9.97%
6,278 $391,000
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $74,968 - $87,815
-1,267 Reduced 15.38%
6,973 $413,000
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $123 - $134
2 Added 0.02%
8,240 $551,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $3,445 - $3,818
-60 Reduced 0.72%
8,238 $497,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $102,012 - $133,065
2,073 Added 33.3%
8,298 $533,000
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $85 - $101
2 Added 0.03%
6,225 $316,000
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $133 - $148
3 Added 0.05%
6,223 $282,000
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $135 - $161
3 Added 0.05%
6,220 $297,000
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $97 - $126
2 Added 0.03%
6,217 $323,000
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $165 - $186
3 Added 0.05%
6,215 $386,000
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $2,577 - $3,211
51 Added 0.83%
6,212 $344,000
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $119 - $137
2 Added 0.03%
6,161 $390,000
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $119 - $130
2 Added 0.03%
6,159 $377,000
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $340,051 - $392,447
6,157
6,157 $392,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Southeast Asset Advisors Inc. Portfolio

Follow Southeast Asset Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Southeast Asset Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Southeast Asset Advisors Inc. with notifications on news.